Serological Responses and Vaccine Effectiveness for Extended COVID-19 Vaccine Schedules in England

Overview

Journal Nat Commun

Specialty Biology

Date 2021 Dec 11

PMID 34893611

Citations 62

Authors

Gayatri Amirthalingam

Jamie Lopez Bernal

Nick J Andrews

Heather Whitaker

Charlotte Gower

Julia Stowe

Elise Tessier

Sathyavani Subbarao

Georgina Ireland

Frances Baawuah

Ezra Linley

Lenesha Warrener

Michelle OBrien

Corinne Whillock

Paul Moss

Shamez N Ladhani

Kevin E Brown

Mary E Ramsay

Affiliations

Soon will be listed here.

Abstract

The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50-89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14-35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65-84 days) compared with those vaccinated with a standard (19-29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14-35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with dose interval. Higher dose two VE was observed with >6 week interval between BNT162b2 doses compared to the standard schedule. Our findings suggest higher effectiveness against infection using an extended vaccine schedule. Given global vaccine constraints these results are relevant to policymakers.

Citing Articles

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.

Zhou G, Dael N, Verweij S, Balafas S, Mubarik S, Oude Rengerink K Eur Respir Rev. 2025; 34(175).

PMID: 39971395 PMC: 11836669. DOI: 10.1183/16000617.0222-2024.

Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen.

Casmil I, Bathula N, Huang C, Wayne C, Cairns E, Friesen J Mol Ther. 2025; 33(2):514-528.

PMID: 39741413 PMC: 11852984. DOI: 10.1016/j.ymthe.2024.12.055.

Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents.

Tsang T, Sullivan S, Meng Y, Lai F, Fan M, Huang X BMC Med. 2024; 22(1):384.

PMID: 39267060 PMC: 11396738. DOI: 10.1186/s12916-024-03597-4.

Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents.

Tsang T, Sullivan S, Meng Y, Lai F, Fan M, Huang X Res Sq. 2024; .

PMID: 38947018 PMC: 11213226. DOI: 10.21203/rs.3.rs-4518813/v1.

Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis.

Tsang T, Sullivan S, Huang X, Wang C, Wang Y, Nealon J Am J Epidemiol. 2024; 193(12):1868-1881.

PMID: 38904437 PMC: 11637527. DOI: 10.1093/aje/kwae142.

References

Ledgerwood J, Zephir K, Hu Z, Wei C, Chang L, Enama M . Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013; 208(3):418-22. PMC: 3699006. DOI: 10.1093/infdis/jit180. View

Collier D, Ferreira I, Kotagiri P, Datir R, Lim E, Touizer E . Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021; 596(7872):417-422. PMC: 8373615. DOI: 10.1038/s41586-021-03739-1. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Parry H, Bruton R, Stephens C, Bentley C, Brown K, Amirthalingam G . Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines. 2022; 7(1):14. PMC: 8795435. DOI: 10.1038/s41541-022-00432-w. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Wei J, Stoesser N, Matthews P, Ayoubkhani D, Studley R, Bell I . Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021; 6(9):1140-1149. PMC: 8294260. DOI: 10.1038/s41564-021-00947-3. View

de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G . Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020; 20(9):1034-1042. PMC: 7228715. DOI: 10.1016/S1473-3099(20)30371-6. View

Clift A, Coupland C, Keogh R, Diaz-Ordaz K, Williamson E, Harrison E . Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020; 371:m3731. PMC: 7574532. DOI: 10.1136/bmj.m3731. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021; 397(10277):881-891. PMC: 7894131. DOI: 10.1016/S0140-6736(21)00432-3. View

10.

Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373:n1088. PMC: 8116636. DOI: 10.1136/bmj.n1088. View

11.

Earle K, Ambrosino D, Fiore-Gartland A, Goldblatt D, B Gilbert P, Siber G . Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021; 39(32):4423-4428. PMC: 8142841. DOI: 10.1016/j.vaccine.2021.05.063. View

12.

Harris R, Whitaker H, Andrews N, Aiano F, Amin-Chowdhury Z, Flood J . Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J Infect. 2021; 82(5):162-169. PMC: 7982645. DOI: 10.1016/j.jinf.2021.03.015. View

13.

Jung K, Shin S, Nam M, Hong Y, Roh E, Park K . Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls. J Clin Lab Anal. 2021; 35(9):e23921. PMC: 8418513. DOI: 10.1002/jcla.23921. View

14.

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

15.

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

16.

Subbarao S, Warrener L, Hoschler K, Perry K, Shute J, Whitaker H . Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill. 2021; 26(12). PMC: 7995559. DOI: 10.2807/1560-7917.ES.2021.26.12.2100329. View

17.

Ladhani S, Jeffery-Smith A, Patel M, Janarthanan R, Fok J, Crawley-Boevey E . High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. EClinicalMedicine. 2020; 28:100597. PMC: 7644437. DOI: 10.1016/j.eclinm.2020.100597. View

18.

Pollard A, Bijker E . A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2020; 21(2):83-100. PMC: 7754704. DOI: 10.1038/s41577-020-00479-7. View

19.

Perkmann T, Koller T, Perkmann-Nagele N, Klausberger M, Duerkop M, Holzer B . Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results. Microbiol Spectr. 2021; 9(1):e0021821. PMC: 8552595. DOI: 10.1128/Spectrum.00218-21. View

20.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View